Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
Precision Perspectives: Navigating Advancements in HR+ / HER2 Negative Breast Cancer Care : Episode 11
Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events
A medical expert compares CDK4/6 inhibitors and discusses the importance of monitoring specific parameters, such as ECGs and laboratory tests, to minimize adverse events associated with each drug.
EP: 1.Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer
EP: 2.Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer
EP: 3.CDK4/6 Inhibitors as First-Line Options in Metastatic Breast Cancer
EP: 4.Treatment Algorithms for Early and Metastatic Breast Cancer
EP: 5.NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer
EP: 6.Evaluating the Impact of Metastatic Breast Cancer on Patients
EP: 7.Highlighting the Available CDK4/6 Inhibitors
EP: 8.Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC
EP: 9.Applying NCCN Guidelines in the Treatment of mBC
EP: 10.CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC
Now Viewing
EP: 11.Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events
EP: 12.Navigating Financial Barriers: Cost-Saving Strategies and Patient Assistance Programs
EP: 13.Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer
EP: 14.Academic and Community Practice Collaboration in mBC Treatment
EP: 15.Defining the Standard of Care for Early Breast Cancer Treatment
EP: 16.Balancing Clinical and Economic Factors in Early Breast Cancer Treatment
EP: 17.Alternative Treatments for eBC and mBC
Related Videos
Related Content
